| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
Purity: ≥98%
Betamethasone Dipropionate (Alphatrex; BetaVal; Diprolene; SCH-11460; SCH11460; Diprolene AF; Diprosone; Luxiq; Betamethasone 17,21-dipropionate) is a synthetic glucocorticoid steroid with anti-inflammatory and immunosuppressive activities. It is approved as a topical cream, ointment, lotion or gel (Diprolene) to treat itching and other minor skin conditions such as eczema.
| ln Vivo |
Psoriasis, dermatitis, and eczema are inflammatory skin disorders that are treated with betomethona dipropionate, an extremely strong corticosteroid. This is an artificial counterpart of adrenocortical steroids.
Efficacy in seborrhoeic dermatitis: Topical Betamethasone Dipropionate significantly improved clinical symptoms of seborrhoeic dermatitis (including erythema, scaling, pruritus, and inflammation) compared to placebo. After 2-4 weeks of treatment, the proportion of patients achieving "clear" or "markedly improved" status ranged from 65% to 82% [1] - Superiority to milder corticosteroids: Betamethasone Dipropionate showed greater efficacy than low-potency topical corticosteroids (e.g., hydrocortisone) in reducing severe scaling and pruritus, with a mean symptom score reduction of 40-55% versus 20-30% in the low-potency group [1] - Relapse prevention: Continuous low-dose maintenance therapy with Betamethasone Dipropionate (2-3 times weekly) reduced the relapse rate of seborrhoeic dermatitis by 38% compared to no maintenance therapy over a 12-week follow-up [1] |
|---|---|
| Toxicity/Toxicokinetics |
Local skin adverse reactions: The most common adverse reaction to topical betamethasone dipropionate is mild to moderate local irritation (12-18% of patients), including burning, stinging and dryness. These reactions are usually transient and resolve upon discontinuation of the drug [1]. - Long-term use risk: Long-term (≥8 weeks) continuous use of betamethasone dipropionate is associated with an increased risk of skin atrophy (4-6% of patients), telangiectasia (2-3%) and hypopigmentation (1-2%) [1]. - Systemic absorption risk: Systemic absorption has been minimal when used topically; no significant changes in serum cortisol levels or systemic corticosteroid-related adverse reactions (e.g., hypertension, hyperglycemia) have been reported in clinical trials [1].
|
| References |
Cochrane Database Syst Rev. 2013 Jan 31;1:CD007633.doi: 10.1002/14651858.CD007633.pub2.
|
| Additional Infomation |
Betamethasone dipropionate is a steroidal ester, a derivative of betamethasone, in which the hydroxyl hydrogens at positions 17 and 21 are replaced by propionyl groups. It is used in combination with the synthetic vitamin D analog calcipotriol hydrate for the topical treatment of adult plaque psoriasis. It has anti-psoriatic activity. It is a steroidal ester, 11β-hydroxysteroid, 20-oxosteroid, fluorosteroid, propionate, and 3-oxo-Δ⁹Δ⁴steroid. It is functionally related to betamethasone. Betamethasone dipropionate has been reported in Dodonaea polyandra, with relevant data available. Betamethasone dipropionate is the 17,21-dipropionate of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive, and anti-inflammatory effects. Betamethasone dipropionate binds to specific intracellular glucocorticoid receptors, subsequently binding to DNA, thereby altering gene expression. It induces the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Therefore, chronic inflammation and autoimmune reactions are generally reduced. See also: betamethasone (with active fraction); betamethasone dipropionate; calcipotriol (component); betamethasone dipropionate; clotrimazole (component)... See more...
Betamethasone dipropionate is a medium-potency topical corticosteroid used to treat inflammatory skin conditions, including seborrheic dermatitis[1] - Its efficacy in treating seborrheic dermatitis is achieved through anti-inflammatory, antipruritic, and antikeratotic effects[1] - A Cochrane systematic review concluded that topical betamethasone dipropionate is effective for short-term (2-4 weeks) treatment of moderate to severe seborrheic dermatitis, but long-term continuous use should be avoided to minimize local skin adverse reactions[1] |
| Molecular Formula |
C28H37FO7
|
|
|---|---|---|
| Molecular Weight |
504.59
|
|
| Exact Mass |
504.252
|
|
| CAS # |
5593-20-4
|
|
| Related CAS # |
Betamethasone;378-44-9;Beclometasone dipropionate;5534-09-8;Beclometasone dipropionate monohydrate;77011-63-3;Betamethasone dipropionate-d10;2280940-19-2
|
|
| PubChem CID |
21800
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Boiling Point |
603.2±55.0 °C at 760 mmHg
|
|
| Melting Point |
178 °C
|
|
| Flash Point |
318.6±31.5 °C
|
|
| Vapour Pressure |
0.0±3.9 mmHg at 25°C
|
|
| Index of Refraction |
1.550
|
|
| LogP |
4.42
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
8
|
|
| Rotatable Bond Count |
8
|
|
| Heavy Atom Count |
36
|
|
| Complexity |
1050
|
|
| Defined Atom Stereocenter Count |
8
|
|
| SMILES |
CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)OC(=O)CC
|
|
| InChi Key |
CIWBQSYVNNPZIQ-XYWKZLDCSA-N
|
|
| InChi Code |
InChI=1S/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
|
|
| Chemical Name |
(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-(propionyloxy)acetyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.75 mg/mL (5.45 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (5.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9818 mL | 9.9090 mL | 19.8181 mL | |
| 5 mM | 0.3964 mL | 1.9818 mL | 3.9636 mL | |
| 10 mM | 0.1982 mL | 0.9909 mL | 1.9818 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA